




# 4

# FIGURE 1A



# FIGURE 1B

**FIGURE 2**

# FIGURE 3




FIGURE 4




FIGURE 5







FIGURE 6





**FIGURE 7**

**FIGURE 8**




## FIGURE 9




**FIGURE 10**

# FIGURE 11



# FIGURE 12



# FIGURE 13

CMT 64 Transfectants +/- VSV



# FIGURE 14

TAP 1 versus TAP 2 CMT 64 Transfectants +/- VSV






FIGURE 15

CMT 64 Transfectants +/- VSV



## FIGURE 16


### CTL Response to Influenza






# FIGURE 17

## CTL Response to Influenza




## FIGURE 18

### CTL Response to Influenza



# FIGURE 19

## CTL Response to HSV-1



**FIGURE 20**

Survival of C57BL/6 and Balb/C Mice Injected with  $5 \times 10^5$  CMT.64 or CMT.12.12





FIGURE 21

A



B





FIGURE 22

A



B





FIGURE 23



**B**

	VV-NP	VV-NP + VV-hTAP12
VSV pCTL	1/78,000	1/16,000

FIGURE 24






FIGURE 25




FIGURE 26




FIGURE 27




FIGURE 28

A

**Murine Splenocytes**

---

Human TAP1 —————

Normal Control  $3 \times 10^4$   $3 \times 10^5$

---

**VV-TAP1,2**

B





FIGURE 29





**FIGURE 30****A****B**

FIGURE 31





FIGURE 32A






FIGURE 32B




FIGURE 33

## TAP1 enhanced the presentation of VSV-NP by B16 cells




FIGURE 34

## TAP1 enhanced the presentation of TRP-2 by B16 cells




FIGURE 35




FIGURE 36





FIGURE 37



## FIGURE 38

A

Tumor	one month		two months		Ratio <sup>b</sup>	
	CD4% <sup>a</sup>	CD8%	CD4%	CD8%	CD4	CD8
CMT.neo	0.54	0.41				
CMT.1-1	1.02	0.87			1.9	2.1
CMT.1-4			1.07	1.20	2.0	2.9
CMT.1-10	4.19	2.94			7.8	7.2
CMT.2-1	0.24	0.23			0.4	0.6
CMT.2-10	0.12	0.66			0.2	1.6

B




FIGURE 39






FIGURE 40

